Cochrane · systematic review · CD012208
Treatment regimens for administration of anti‐vascular endothelial growth factor agents for neovascular age‐related macular degeneration
Li, E, Donati, S, Lindsley, KB, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
Eyes and VisionAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
12
No studies
1
Included studies
NR
No studies 1 · 7.1%Ungraded 1 · 7.1%Very low 0 · 0%Low 5 · 35.7%Moderate 7 · 50%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
As needed compared to monthly injections for administration of anti‐vascular endothelial growth factor agents for neovascular age‐related macular degeneration
Population: people with neovascular age‐related macular degeneration
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in BCVA at 1 year (ETDRS letters score, the higher the score the better) As needed vs monthly injections | no estimate extracted | 4 studies · 2299 participants | Moderate Downgraded: risk of bias |
Gain of ≥ 15 letters visual acuity at 1 year As needed vs monthly injections | RR 0.87 [0.76, 0.99] | 4 studies · 2299 participants | Low Downgraded: risk of bias, imprecision |
Change in central retinal thickness at 1 year (μm, the thinner the better on average) As needed vs monthly injections | no estimate extracted | 4 studies · 2215 participants | Moderate Downgraded: risk of bias |
Change in QoL scores at 1 year (higher was better) As needed vs monthly injections | no estimate extracted | 1 study · 498 participants | Low Downgraded: risk of bias, imprecision |
Number of injections at 1 year As needed vs monthly injections | no estimate extracted | 4 studies · 2336 participants | Moderate Downgraded: risk of bias |
Cost of treatment per person at 1 year As needed vs monthly injections | no estimate extracted | 2 studies · 1105 participants | Low Downgraded: imprecision, indirectness |
Endophthalmitis (ocular adverse event) As needed vs monthly injections | Peto OR 0.13 [0.04, 0.46] | 6 studies · 3175 participants | Moderate Downgraded: risk of bias |
Extended‐fixed compared to monthly injections for administration of anti‐vascular endothelial growth factor agents for neovascular age‐related macular degeneration
Population: people with neovascular age‐related macular degeneration
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in BCVA at 1 year (ETDRS letters score, the higher the score the better) Extended‐fixed vs monthly injections | no estimate extracted | 3 studies · 1439 participants | Moderate Downgraded: risk of bias |
Gain of ≥ 15 letters visual acuity at 1 year Extended‐fixed vs monthly injections | RR 0.94 [0.8, 1.1] | 3 studies · 1441 participants | Moderate Downgraded: risk of bias |
Change in central retinal thickness at 1 year (μm, the thinner the better on average) Extended‐fixed vs monthly injections | no estimate extracted | 3 studies · 1439 participants | Low Downgraded: risk of bias, imprecision |
Change in QoL score at 1 year ( Extended‐fixed vs monthly injections | no estimate extracted | 1 study · 1220 participants | Moderate Downgraded: risk of bias |
Number of injections at 1 year Extended‐fixed vs monthly injections | 8 | 1 study · 1220 participants | Ungraded |
Cost of treatment per person at 1 year Extended‐fixed vs monthly injections | no estimate extracted | NR | No studies |
Endophthalmitis (ocular adverse event) Extended‐fixed vs monthly injections | RR 0.19 [0.03, 1.12] | 3 studies · 1132 participants | Low Downgraded: risk of bias, imprecision |